CD274 and non-small cell lung carcinoma: DEBIO 1143 is also being assessed in a multi-center, open-label phase-Ib study evaluating the combination with the anti-PD-L1 antibody avelumab in patients with advanced solid malignancies and, in an expansion cohort, in patients with locally advanced or metastatic non-small cell lung cancer (NCT03270176).